Development and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies

Cited 1 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorY J Chae-
dc.contributor.authorYoo-Kyung Song-
dc.contributor.authorSong Hee Chae-
dc.contributor.authorMin Ju Kim-
dc.contributor.authorJong Soon Kang-
dc.contributor.authorJ Y Lee-
dc.contributor.authorT S Koo-
dc.contributor.authorKyeong-Ryoon Lee-
dc.date.accessioned2020-09-24T03:29:42Z-
dc.date.available2020-09-24T03:29:42Z-
dc.date.issued2020-
dc.identifier.issn20933134-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/22696-
dc.description.abstractLarotrectinib is an orally administered drug and the first and only selective pan-tropomyosin receptor kinase (TRK) inhibitor in clinical development to treat cancer patients harboring a neurotrophic receptor tyrosine kinase gene fusion. In this study, an analytical method to quantify the TRK inhibitor in mouse and human plasma was developed and validated using LC-MS/MS following protein precipitation with acetonitrile. Larotrectinib and an internal standard (carbamazepine) were separated from endogenous substances using an Xterra C18 column with acetonitrile containing 0.1% formic acid as the mobile phase. The ions m/z 429.8 → 342.8 for larotrectinib and m/z 237.0 → 194.0 for carbamazepine detected in multiple reaction monitoring mode were used for the quantitation. The detector response of larotrectinib was linear within the concentration range 5-10,000 ng/mL with a correlation coefficient (r2) of not less than 0.999. The intra- and inter-day precision and accuracy were less than 10.48% and within -8.99%, respectively, in mouse and human plasma. Larotrectinib was stable under various storage and handling conditions, and no significant matrix effect was observed in both mouse and human plasma. Finally, the assay was successfully applied to the pharmacokinetic study of larotrectinib after its intravenous and oral administration to mice.-
dc.publisherSpringer-
dc.titleDevelopment and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies-
dc.title.alternativeDevelopment and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies-
dc.typeArticle-
dc.citation.titleJournal of Analytical Science and Technology-
dc.citation.number0-
dc.citation.endPage20-
dc.citation.startPage20-
dc.citation.volume11-
dc.contributor.affiliatedAuthorYoo-Kyung Song-
dc.contributor.affiliatedAuthorSong Hee Chae-
dc.contributor.affiliatedAuthorMin Ju Kim-
dc.contributor.affiliatedAuthorJong Soon Kang-
dc.contributor.affiliatedAuthorKyeong-Ryoon Lee-
dc.contributor.alternativeName채윤지-
dc.contributor.alternativeName송유경-
dc.contributor.alternativeName채송희-
dc.contributor.alternativeName김민주-
dc.contributor.alternativeName강종순-
dc.contributor.alternativeName이재영-
dc.contributor.alternativeName구태성-
dc.contributor.alternativeName이경륜-
dc.identifier.bibliographicCitationJournal of Analytical Science and Technology, vol. 11, pp. 20-20-
dc.identifier.doi10.1186/s40543-020-00219-5-
dc.subject.keywordLarotrectinib-
dc.subject.keywordTRK inhibitor-
dc.subject.keywordPharmacokinetics-
dc.subject.keywordMass spectrometry-
dc.subject.localLarotrectinib-
dc.subject.localTRK inhibitor-
dc.subject.localPharmacokinetics-
dc.subject.localMass spectrometry-
dc.subject.localMass spectrometry (MS)-
dc.description.journalClassY-
Appears in Collections:
Ochang Branch Institute > Division of Bioinfrastructure > Laboratory Animal Resource Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.